<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26668438</article-id><article-id pub-id-type="pmc">4669726</article-id><article-id pub-id-type="publisher-id">BLT.14.151167</article-id><article-id pub-id-type="doi">10.2471/BLT.14.151167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Policy &#x00026; Practice</subject></subj-group></article-categories><title-group><article-title>Rapid diagnostic tests for malaria</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Tests de diagnostic rapide du paludisme</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Pruebas de diagn&#x000f3;stico r&#x000e1;pido del paludismo</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00639;&#x00629; &#x00644;&#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635; &#x00627;&#x00644;&#x00645;&#x00644;&#x00627;&#x00631;&#x0064a;&#x00627; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x0759f;&#x075be;&#x05feb;&#x0901f;&#x08bca;&#x065ad;&#x06d4b;&#x08bd5;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x00414;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00435; &#x0044d;&#x0043a;&#x00441;&#x0043f;&#x00440;&#x00435;&#x00441;&#x00441;-&#x00442;&#x00435;&#x00441;&#x00442;&#x0044b; &#x0043d;&#x00430; &#x0043c;&#x00430;&#x0043b;&#x0044f;&#x00440;&#x00438;&#x0044e;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Theodoor Visser et al.</alt-title><alt-title alt-title-type="title-running-head">Diagnostic tests for malaria</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Visser</surname><given-names>Theodoor</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Daily</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hotte</surname><given-names>Nora</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dolkart</surname><given-names>Caitlin</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cunningham</surname><given-names>Jane</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yadav</surname><given-names>Prashant</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><aff id="aff1"><label>a</label>Clinton Health Access Initiative, Inc., 383 Dorchester Avenue, Suite 400, Boston, MA 02127, United States of America (USA).</aff><aff id="aff2"><label>b</label>Consultant to UNITAID, Denver, <country>USA</country>.</aff><aff id="aff3"><label>c</label>Global Malaria Programme, World Health Organization, Geneva, <country>Switzerland</country>.</aff><aff id="aff4"><label>d</label>William Davidson Institute, University of Michigan, Ann Arbor, <country>USA</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Theodoor Visser (email: <email xlink:href="tvisser@clintonhealthaccess.org">tvisser@clintonhealthaccess.org</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>25</day><month>9</month><year>2015</year></pub-date><volume>93</volume><issue>12</issue><fpage>862</fpage><lpage>866</lpage><history><date date-type="received"><day>15</day><month>12</month><year>2014</year></date><date date-type="rev-recd"><day>20</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>(c) 2015 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><p>Maintaining quality, competitiveness and innovation in global health technology is a constant challenge for manufacturers, while affordability, access and equity are challenges for governments and international agencies. In this paper we discuss these issues with reference to rapid diagnostic tests for malaria. Strategies to control and eliminate malaria depend on early and accurate diagnosis. Rapid diagnostic tests for malaria require little training and equipment and can be performed by non-specialists in remote settings. Use of these tests has expanded significantly over the last few years, following recommendations to test all suspected malaria cases before treatment and the implementation of an evaluation programme to assess the performance of the malaria rapid diagnostic tests. Despite these gains, challenges exist that, if not addressed, could jeopardize the progress made to date. We discuss recent developments in rapid diagnostic tests for malaria, highlight some of the challenges and provide suggestions to address them.</p></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><p>Le maintien de la qualit&#x000e9;, de la comp&#x000e9;titivit&#x000e9; et de l'innovation dans les technologies de la sant&#x000e9; au niveau mondial repr&#x000e9;sente un d&#x000e9;fi constant pour les fabricants, tandis que l'accessibilit&#x000e9; &#x000e9;conomique, l'acc&#x000e8;s et l'&#x000e9;quit&#x000e9; constituent un d&#x000e9;fi pour les gouvernements et les organismes internationaux. Nous abordons ces questions dans le pr&#x000e9;sent rapport en ce qui concerne les tests de diagnostic rapide du paludisme. Les strat&#x000e9;gies visant &#x000e0; enrayer et &#x000e0; &#x000e9;radiquer le paludisme reposent sur un diagnostic pr&#x000e9;coce et pr&#x000e9;cis. Les tests de diagnostic rapide du paludisme n&#x000e9;cessitent peu de formation et de mat&#x000e9;riel et peuvent &#x000ea;tre r&#x000e9;alis&#x000e9;s par des non-sp&#x000e9;cialistes dans des endroits isol&#x000e9;s. L'utilisation de ces tests s'est consid&#x000e9;rablement r&#x000e9;pandue au cours des derni&#x000e8;res ann&#x000e9;es suite aux recommandations pr&#x000e9;conisant d'examiner tous les cas pr&#x000e9;sum&#x000e9;s de paludisme avant la mise en route d'un traitement et de mettre en &#x00153;uvre un programme d'&#x000e9;valuation pour mesurer les performances des tests de diagnostic rapide du paludisme. Il demeure, malgr&#x000e9; ces avanc&#x000e9;es, des d&#x000e9;fis, qui, s'ils ne sont pas surmont&#x000e9;s, risquent de compromettre les progr&#x000e8;s accomplis jusqu'&#x000e0; pr&#x000e9;sent. Le pr&#x000e9;sent rapport fait &#x000e9;tat des am&#x000e9;liorations r&#x000e9;cemment apport&#x000e9;es aux tests de diagnostic rapide du paludisme, souligne un certain nombre de d&#x000e9;fis et propose des solutions pour les surmonter.</p></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><p>Mantener la calidad, competitividad e innovaci&#x000f3;n en la tecnolog&#x000ed;a de salud mundial es un desaf&#x000ed;o constante para los fabricantes, mientras que la asequibilidad, el acceso y la equidad son desaf&#x000ed;os para los gobiernos y las agencias internacionales. En este art&#x000ed;culo se debaten estas cuestiones con relaci&#x000f3;n a las pruebas de diagn&#x000f3;stico r&#x000e1;pido del paludismo. Las estrategias para controlar y eliminar el paludismo dependen de un diagn&#x000f3;stico temprano y preciso. Las pruebas de diagn&#x000f3;stico r&#x000e1;pido del paludismo requieren muy poco entrenamiento y equipo y pueden ser llevadas a cabo por no especialistas en lugares apartados. La utilizaci&#x000f3;n de estas pruebas se ha expandido significantemente durante los &#x000fa;ltimos a&#x000f1;os, tras las recomendaciones de hacer una prueba en todos los casos de posible paludismo antes del tratamiento y la implementaci&#x000f3;n de un programa de evaluaci&#x000f3;n para examinar el rendimiento de las pruebas de diagn&#x000f3;stico r&#x000e1;pido del paludismo. A pesar de estos avances, todav&#x000ed;a existen desaf&#x000ed;os que, si no se abordan, podr&#x000ed;an poner en peligro el progreso hecho hasta la fecha. Se debaten los recientes desarrollos de las pruebas de diagn&#x000f3;stico r&#x000e1;pido del paludismo, se destacan algunos de los desaf&#x000ed;os y se proporcionan sugerencias para tratarlos.</p></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><p>&#x0064a;&#x00645;&#x0062b;&#x00644; &#x00627;&#x00644;&#x0062d;&#x00641;&#x00627;&#x00638; &#x00639;&#x00644;&#x00649; &#x00645;&#x00633;&#x0062a;&#x00648;&#x00649; &#x00627;&#x00644;&#x0062c;&#x00648;&#x0062f;&#x00629;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00642;&#x0062f;&#x00631;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00646;&#x00627;&#x00641;&#x00633;&#x0064a;&#x00629;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00627;&#x00628;&#x0062a;&#x00643;&#x00627;&#x00631; &#x00641;&#x0064a; &#x00645;&#x0062c;&#x00627;&#x00644; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00644;&#x00645;&#x0064a;&#x00629; &#x0062a;&#x0062d;&#x0062f;&#x0064a;&#x0064b;&#x00627; &#x00623;&#x00645;&#x00627;&#x00645; &#x00627;&#x00644;&#x0062c;&#x00647;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00635;&#x00646;&#x00639;&#x00629;&#x0060c; &#x00628;&#x0064a;&#x00646;&#x00645;&#x00627; &#x0062a;&#x00648;&#x00627;&#x0062c;&#x00647; &#x00627;&#x00644;&#x0062d;&#x00643;&#x00648;&#x00645;&#x00627;&#x0062a; &#x00648;&#x00627;&#x00644;&#x00648;&#x00643;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00644;&#x0064a;&#x00629; &#x0062a;&#x0062d;&#x0062f;&#x0064a;&#x00627;&#x0062a; &#x00623;&#x0062e;&#x00631;&#x00649; &#x0062a;&#x0062a;&#x00645;&#x0062b;&#x00644; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00625;&#x00646;&#x00635;&#x00627;&#x00641;&#x0060c; &#x00648;&#x00645;&#x00639;&#x00642;&#x00648;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00623;&#x00633;&#x00639;&#x00627;&#x00631;&#x0060c; &#x00648;&#x00625;&#x00645;&#x00643;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062d;&#x00635;&#x00648;&#x00644; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062e;&#x0062f;&#x00645;&#x00627;&#x0062a;. &#x00648;&#x00646;&#x00646;&#x00627;&#x00642;&#x00634; &#x00641;&#x0064a; &#x00647;&#x00630;&#x00627; &#x00627;&#x00644;&#x0062a;&#x00642;&#x00631;&#x0064a;&#x00631; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00642;&#x00636;&#x00627;&#x0064a;&#x00627; &#x00641;&#x0064a;&#x00645;&#x00627; &#x0064a;&#x0062a;&#x00639;&#x00644;&#x00642; &#x00628;&#x00634;&#x00623;&#x00646; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00639;&#x00629; &#x00644;&#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635; &#x00627;&#x00644;&#x00645;&#x00644;&#x00627;&#x00631;&#x0064a;&#x00627;. &#x0062a;&#x00639;&#x0062a;&#x00645;&#x0062f; &#x00627;&#x00633;&#x0062a;&#x00631;&#x00627;&#x0062a;&#x0064a;&#x0062c;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x0064a;&#x00637;&#x00631;&#x00629; &#x00639;&#x00644;&#x00649; &#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00645;&#x00644;&#x00627;&#x00631;&#x0064a;&#x00627; &#x00648;&#x00627;&#x00644;&#x00642;&#x00636;&#x00627;&#x00621; &#x00639;&#x00644;&#x0064a;&#x00647; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635; &#x00627;&#x00644;&#x00645;&#x00628;&#x00643;&#x00631; &#x00648;&#x00627;&#x00644;&#x0062f;&#x00642;&#x0064a;&#x00642; &#x00644;&#x00644;&#x00645;&#x00631;&#x00636;. &#x00648;&#x0062a;&#x0062a;&#x00637;&#x00644;&#x00628; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00639;&#x00629; &#x00644;&#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635; &#x00627;&#x00644;&#x00645;&#x00644;&#x00627;&#x00631;&#x0064a;&#x00627; &#x00627;&#x00644;&#x00642;&#x00644;&#x0064a;&#x00644; &#x00645;&#x00646; &#x00627;&#x00644;&#x0062a;&#x0062f;&#x00631;&#x0064a;&#x00628; &#x00648;&#x00627;&#x00644;&#x00645;&#x00639;&#x0062f;&#x00627;&#x0062a;&#x0060c; &#x00643;&#x00645;&#x00627; &#x0064a;&#x00645;&#x00643;&#x00646; &#x00625;&#x0062c;&#x00631;&#x00627;&#x00624;&#x00647;&#x00627; &#x00639;&#x00644;&#x00649; &#x0064a;&#x0062f; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0062e;&#x00635;&#x00635;&#x0064a;&#x00646; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00637;&#x00642; &#x00627;&#x00644;&#x00646;&#x00627;&#x00626;&#x0064a;&#x00629;. &#x00648;&#x00642;&#x0062f; &#x00627;&#x0062a;&#x00633;&#x00639; &#x00646;&#x00637;&#x00627;&#x00642; &#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00627;&#x0062a; &#x00628;&#x00635;&#x00648;&#x00631;&#x00629; &#x00645;&#x00644;&#x0062d;&#x00648;&#x00638;&#x00629; &#x00639;&#x00644;&#x00649; &#x00645;&#x0062f;&#x00649; &#x00627;&#x00644;&#x00633;&#x00646;&#x00648;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00642;&#x00644;&#x0064a;&#x00644;&#x00629; &#x00627;&#x00644;&#x00645;&#x00627;&#x00636;&#x0064a;&#x00629; &#x00646;&#x0062a;&#x0064a;&#x0062c;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00648;&#x00635;&#x0064a;&#x00627;&#x0062a; &#x00628;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x0062c;&#x00645;&#x0064a;&#x00639; &#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00627;&#x00634;&#x0062a;&#x00628;&#x00627;&#x00647; &#x00628;&#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00645;&#x00644;&#x00627;&#x00631;&#x0064a;&#x00627; &#x00642;&#x00628;&#x00644; &#x00627;&#x00644;&#x00628;&#x0062f;&#x00621; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00648;&#x0062a;&#x00646;&#x00641;&#x0064a;&#x00630; &#x00628;&#x00631;&#x00646;&#x00627;&#x00645;&#x0062c; &#x00644;&#x00644;&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; &#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00645;&#x00633;&#x0062a;&#x00648;&#x00649; &#x00627;&#x00644;&#x00623;&#x0062f;&#x00627;&#x00621; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00639;&#x00644;&#x00642; &#x00628;&#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00639;&#x00629; &#x00644;&#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635; &#x00627;&#x00644;&#x00645;&#x00644;&#x00627;&#x00631;&#x0064a;&#x00627;. &#x00648;&#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00631;&#x0063a;&#x00645; &#x00645;&#x00646; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00645;&#x00643;&#x00627;&#x00633;&#x00628;&#x0060c; &#x00645;&#x00627; &#x00632;&#x00627;&#x00644;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x0062f;&#x0064a;&#x00627;&#x0062a; &#x00642;&#x00627;&#x00626;&#x00645;&#x00629; &#x00644;&#x00644;&#x0062d;&#x0062f; &#x00627;&#x00644;&#x00630;&#x0064a; &#x00642;&#x0062f; &#x0064a;&#x00624;&#x0062f;&#x0064a; &#x00625;&#x00644;&#x00649; &#x0062e;&#x00633;&#x00627;&#x00631;&#x00629; &#x00645;&#x00627; &#x0062a;&#x00645; &#x00625;&#x0062d;&#x00631;&#x00627;&#x00632;&#x00647; &#x00645;&#x00646; &#x0062a;&#x00642;&#x0062f;&#x00645; &#x0062d;&#x0062a;&#x00649; &#x00627;&#x00644;&#x00648;&#x00642;&#x0062a; &#x00627;&#x00644;&#x0062d;&#x00627;&#x00644;&#x0064a;&#x0060c; &#x00625;&#x00646; &#x00644;&#x00645; &#x0062a;&#x0062a;&#x00645; &#x00645;&#x00648;&#x00627;&#x0062c;&#x00647;&#x0062a;&#x00647;&#x00627;. &#x00648;&#x00646;&#x00646;&#x00627;&#x00642;&#x00634; &#x00627;&#x00644;&#x0062a;&#x00637;&#x00648;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00623;&#x0062e;&#x0064a;&#x00631;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00639;&#x00644;&#x00642;&#x00629; &#x00628;&#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00639;&#x00629; &#x00644;&#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635; &#x00627;&#x00644;&#x00645;&#x00644;&#x00627;&#x00631;&#x0064a;&#x00627;&#x0060c; &#x00648;&#x00646;&#x00644;&#x00642;&#x0064a; &#x00627;&#x00644;&#x00636;&#x00648;&#x00621; &#x00639;&#x00644;&#x00649; &#x00628;&#x00639;&#x00636; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x0062f;&#x0064a;&#x00627;&#x0062a;&#x0060c; &#x00648;&#x00646;&#x00642;&#x0062f;&#x00645; &#x00628;&#x00639;&#x00636; &#x00627;&#x00644;&#x00627;&#x00642;&#x0062a;&#x00631;&#x00627;&#x0062d;&#x00627;&#x0062a; &#x00644;&#x00645;&#x00648;&#x00627;&#x0062c;&#x00647;&#x0062a;&#x00647;&#x00627;. </p></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><p>&#x04fdd;&#x06301;&#x05168;&#x07403;&#x0536b;&#x0751f;&#x06280;&#x0672f;&#x07684;&#x08d28;&#x091cf;&#x03001;&#x07ade;&#x04e89;&#x0529b;&#x0548c;&#x0521b;&#x065b0;&#x0662f;&#x05236;&#x09020;&#x05546;&#x04e0d;&#x065ad;&#x09762;&#x04e34;&#x07684;&#x06311;&#x06218;&#x0ff0c;&#x0800c;&#x0653f;&#x05e9c;&#x0548c;&#x056fd;&#x09645;&#x0673a;&#x06784;&#x05219;&#x09762;&#x04e34;&#x07740;&#x0652f;&#x04ed8;&#x080fd;&#x0529b;&#x03001;&#x053ef;&#x08fd1;&#x06027;&#x0548c;&#x0516c;&#x05e73;&#x06027;&#x07684;&#x06311;&#x06218;&#x03002;&#x0672c;&#x06587;&#x05c06;&#x063a2;&#x08ba8;&#x05173;&#x04e8e;&#x0759f;&#x075be;&#x05feb;&#x0901f;&#x08bca;&#x065ad;&#x06d4b;&#x08bd5;&#x07684;&#x08fd9;&#x04e9b;&#x095ee;&#x09898;&#x03002;&#x063a7;&#x05236;&#x0548c;&#x06d88;&#x09664;&#x0759f;&#x075be;&#x07684;&#x07b56;&#x07565;&#x053d6;&#x051b3;&#x04e8e;&#x053ca;&#x065e9;&#x03001;&#x051c6;&#x0786e;&#x07684;&#x08bca;&#x065ad;&#x03002;&#x0800c;&#x0759f;&#x075be;&#x05feb;&#x0901f;&#x08bca;&#x065ad;&#x06d4b;&#x08bd5;&#x051e0;&#x04e4e;&#x04e0d;&#x09700;&#x08981;&#x057f9;&#x08bad;&#x0548c;&#x08bbe;&#x05907;&#x0ff0c;&#x04e14;&#x053ef;&#x07531;&#x0975e;&#x04e13;&#x04e1a;&#x04eba;&#x05458;&#x08fdc;&#x07a0b;&#x06267;&#x0884c;&#x03002;&#x08fc7;&#x053bb;&#x051e0;&#x05e74;&#x05185;&#x0ff0c;&#x0968f;&#x07740;&#x06cbb;&#x07597;&#x0524d;&#x06d4b;&#x08bd5;&#x06240;&#x06709;&#x07591;&#x04f3c;&#x0759f;&#x075be;&#x075c5;&#x04f8b;&#x07684;&#x05efa;&#x08bae;&#x07684;&#x063d0;&#x051fa;&#x0548c;&#x0759f;&#x075be;&#x05feb;&#x0901f;&#x06d4b;&#x08bd5;&#x06027;&#x080fd;&#x08bc4;&#x04f30;&#x09879;&#x076ee;&#x07684;&#x05b9e;&#x065bd;&#x0ff0c;&#x08fd9;&#x04e9b;&#x06d4b;&#x08bd5;&#x07684;&#x04f7f;&#x07528;&#x08303;&#x056f4;&#x05df2;&#x0663e;&#x08457;&#x06269;&#x05927;&#x03002;&#x05c3d;&#x07ba1;&#x053d6;&#x05f97;&#x04e86;&#x08fd9;&#x04e9b;&#x06210;&#x05c31;&#x0ff0c;&#x04ecd;&#x07136;&#x05b58;&#x05728;&#x04e00;&#x04e9b;&#x06311;&#x06218;&#x0ff0c;&#x05982;&#x0679c;&#x04e0d;&#x080fd;&#x059a5;&#x05584;&#x05316;&#x089e3;&#x0ff0c;&#x05b83;&#x04eec;&#x053ef;&#x080fd;&#x05371;&#x053ca;&#x076ee;&#x0524d;&#x04e3a;&#x06b62;&#x06240;&#x053d6;&#x05f97;&#x07684;&#x08fdb;&#x05c55;&#x03002;&#x06211;&#x04eec;&#x05c06;&#x063a2;&#x08ba8;&#x0759f;&#x075be;&#x05feb;&#x0901f;&#x08bca;&#x065ad;&#x07684;&#x06700;&#x065b0;&#x053d1;&#x05c55;&#x0ff0c;&#x07a81;&#x051fa;&#x05176;&#x04e2d;&#x04e00;&#x04e9b;&#x06311;&#x06218;&#x0ff0c;&#x05e76;&#x063d0;&#x051fa;&#x05e94;&#x05bf9;&#x08fd9;&#x04e9b;&#x06311;&#x06218;&#x07684;&#x05efa;&#x08bae;&#x03002;</p></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><p>&#x0041f;&#x0043e;&#x00434;&#x00434;&#x00435;&#x00440;&#x00436;&#x00430;&#x0043d;&#x00438;&#x00435; &#x0043a;&#x00430;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430;, &#x0043a;&#x0043e;&#x0043d;&#x0043a;&#x00443;&#x00440;&#x00435;&#x0043d;&#x00442;&#x0043d;&#x0043e;&#x00439; &#x00441;&#x0043f;&#x0043e;&#x00441;&#x0043e;&#x00431;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00438; &#x00438;&#x0043d;&#x0043d;&#x0043e;&#x00432;&#x00430;&#x00446;&#x00438;&#x00439; &#x00432; &#x0043e;&#x00431;&#x0043b;&#x00430;&#x00441;&#x00442;&#x00438; &#x00442;&#x00435;&#x00445;&#x0043d;&#x0043e;&#x0043b;&#x0043e;&#x00433;&#x00438;&#x00439; &#x0043c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x00433;&#x0043e; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043d;&#x00430; &#x00432;&#x0044b;&#x00441;&#x0043e;&#x0043a;&#x0043e;&#x0043c; &#x00443;&#x00440;&#x0043e;&#x00432;&#x0043d;&#x00435;&#x000a0;&#x02014; &#x0044d;&#x00442;&#x0043e; &#x00437;&#x00430;&#x00434;&#x00430;&#x00447;&#x00430;, &#x0043d;&#x00430;&#x00434; &#x00440;&#x00435;&#x00448;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0043e;&#x00439; &#x0043f;&#x0043e;&#x00441;&#x00442;&#x0043e;&#x0044f;&#x0043d;&#x0043d;&#x0043e; &#x00440;&#x00430;&#x00431;&#x0043e;&#x00442;&#x00430;&#x0044e;&#x00442; &#x00438;&#x00437;&#x00433;&#x0043e;&#x00442;&#x0043e;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x00438;, &#x00432; &#x00442;&#x0043e; &#x00432;&#x00440;&#x00435;&#x0043c;&#x0044f; &#x0043a;&#x00430;&#x0043a; &#x00437;&#x00430;&#x00434;&#x00430;&#x00447;&#x00435;&#x00439; &#x0043f;&#x00440;&#x00430;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x00441;&#x00442;&#x00432; &#x00438; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443;&#x0043d;&#x00430;&#x00440;&#x0043e;&#x00434;&#x0043d;&#x0044b;&#x00445; &#x0043e;&#x00440;&#x00433;&#x00430;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00439; &#x00441;&#x00442;&#x00430;&#x0043d;&#x0043e;&#x00432;&#x00438;&#x00442;&#x00441;&#x0044f; &#x0043e;&#x00431;&#x00435;&#x00441;&#x0043f;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00443;&#x0043f;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;, &#x00446;&#x00435;&#x0043d;&#x0043e;&#x00432;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x00438;&#x00435;&#x0043c;&#x0043b;&#x00435;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00438; &#x00440;&#x00430;&#x00432;&#x00435;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00430; &#x00432; &#x00432;&#x0043e;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00430;&#x00445; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f;. &#x00412; &#x0044d;&#x00442;&#x0043e;&#x00439; &#x00441;&#x00442;&#x00430;&#x00442;&#x0044c;&#x00435; &#x00440;&#x00430;&#x00441;&#x00441;&#x0043c;&#x00430;&#x00442;&#x00440;&#x00438;&#x00432;&#x00430;&#x0044e;&#x00442;&#x00441;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00431;&#x0043b;&#x00435;&#x0043c;&#x0044b;, &#x00441;&#x00432;&#x0044f;&#x00437;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x00441; &#x00431;&#x0044b;&#x00441;&#x00442;&#x00440;&#x0044b;&#x0043c;&#x00438; &#x00441;&#x0043f;&#x0043e;&#x00441;&#x0043e;&#x00431;&#x00430;&#x0043c;&#x00438; &#x00442;&#x00435;&#x00441;&#x00442;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00440;&#x00438; &#x0043f;&#x0043e;&#x00441;&#x00442;&#x00430;&#x0043d;&#x0043e;&#x00432;&#x0043a;&#x00435; &#x00434;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00437;&#x00430; &#x000ab;&#x0043c;&#x00430;&#x0043b;&#x0044f;&#x00440;&#x00438;&#x0044f;&#x000bb;. &#x00412;&#x0044b;&#x00431;&#x0043e;&#x00440; &#x00441;&#x00442;&#x00440;&#x00430;&#x00442;&#x00435;&#x00433;&#x00438;&#x00439; &#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00440;&#x0043e;&#x0043b;&#x0044f; &#x00438; &#x00438;&#x00441;&#x0043a;&#x0043e;&#x00440;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x00430;&#x0043b;&#x0044f;&#x00440;&#x00438;&#x00438; &#x00437;&#x00430;&#x00432;&#x00438;&#x00441;&#x00438;&#x00442; &#x0043e;&#x00442; &#x00432;&#x0043e;&#x00437;&#x0043c;&#x0043e;&#x00436;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00440;&#x00430;&#x0043d;&#x0043d;&#x00435;&#x00439; &#x00438; &#x00442;&#x0043e;&#x00447;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x0043e;&#x00441;&#x00442;&#x00430;&#x0043d;&#x0043e;&#x00432;&#x0043a;&#x00438; &#x00434;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00437;&#x00430;. &#x00414;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00435; &#x0044d;&#x0043a;&#x00441;&#x0043f;&#x00440;&#x00435;&#x00441;&#x00441;-&#x00442;&#x00435;&#x00441;&#x00442;&#x0044b; &#x0043d;&#x00430; &#x0043c;&#x00430;&#x0043b;&#x0044f;&#x00440;&#x00438;&#x0044e; &#x0043d;&#x00435; &#x00442;&#x00440;&#x00435;&#x00431;&#x00443;&#x0044e;&#x00442; &#x00434;&#x0043b;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00443;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00438;&#x0043b;&#x00438; &#x00441;&#x0043f;&#x00435;&#x00446;&#x00438;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x0043e;&#x00440;&#x00443;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00438; &#x0043c;&#x0043e;&#x00433;&#x00443;&#x00442; &#x00432;&#x0044b;&#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x0044f;&#x00442;&#x0044c;&#x00441;&#x0044f; &#x00434;&#x00430;&#x00436;&#x00435; &#x0043d;&#x00435;&#x00441;&#x0043f;&#x00435;&#x00446;&#x00438;&#x00430;&#x0043b;&#x00438;&#x00441;&#x00442;&#x00430;&#x0043c;&#x00438; &#x00432; &#x00443;&#x00441;&#x0043b;&#x0043e;&#x00432;&#x00438;&#x0044f;&#x00445; &#x0043e;&#x00442;&#x00434;&#x00430;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00440;&#x00430;&#x00439;&#x0043e;&#x0043d;&#x0043e;&#x00432;. &#x00417;&#x00430; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043d;&#x00438;&#x00435; &#x0043d;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x0043b;&#x0044c;&#x0043a;&#x0043e; &#x0043b;&#x00435;&#x00442; &#x00442;&#x00430;&#x0043a;&#x00438;&#x00435; &#x00442;&#x00435;&#x00441;&#x00442;&#x0044b; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00438;&#x0043b;&#x00438; &#x00448;&#x00438;&#x00440;&#x0043e;&#x0043a;&#x0043e;&#x00435; &#x00440;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435; &#x00442;&#x0043e;&#x00433;&#x0043e;, &#x0043a;&#x00430;&#x0043a; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00440;&#x00435;&#x0043a;&#x0043e;&#x0043c;&#x00435;&#x0043d;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043e; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00440;&#x0044f;&#x00442;&#x0044c; &#x00432;&#x00441;&#x00435; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00438; &#x0043f;&#x0043e;&#x00434;&#x0043e;&#x00437;&#x00440;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043d;&#x00430; &#x0043c;&#x00430;&#x0043b;&#x0044f;&#x00440;&#x00438;&#x0044e; &#x00434;&#x0043e; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00430; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x00430; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435; &#x0043e;&#x00441;&#x00443;&#x00449;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00438;, &#x0043d;&#x00430;&#x0043f;&#x00440;&#x00430;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x0043d;&#x00430; &#x0043e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0044d;&#x0043a;&#x00441;&#x0043f;&#x00440;&#x00435;&#x00441;&#x00441;-&#x00442;&#x00435;&#x00441;&#x00442;&#x0043e;&#x00432; &#x00434;&#x0043b;&#x0044f; &#x00434;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;&#x0043a;&#x00438; &#x0043c;&#x00430;&#x0043b;&#x0044f;&#x00440;&#x00438;&#x00438;. &#x0041d;&#x00435;&#x00441;&#x0043c;&#x0043e;&#x00442;&#x00440;&#x0044f; &#x0043d;&#x00430; &#x00443;&#x00441;&#x0043f;&#x00435;&#x00445;&#x00438;, &#x00441;&#x00443;&#x00449;&#x00435;&#x00441;&#x00442;&#x00432;&#x00443;&#x00435;&#x00442; &#x00440;&#x0044f;&#x00434; &#x0043f;&#x00440;&#x0043e;&#x00431;&#x0043b;&#x00435;&#x0043c;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00435; &#x0043c;&#x0043e;&#x00433;&#x00443;&#x00442; &#x0043f;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x00442;&#x0044c; &#x0043f;&#x0043e;&#x00434; &#x00443;&#x00433;&#x00440;&#x0043e;&#x00437;&#x00443; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00438;&#x00433;&#x0043d;&#x00443;&#x00442;&#x0044b;&#x00439; &#x0043d;&#x00430; &#x00441;&#x00435;&#x00433;&#x0043e;&#x00434;&#x0043d;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00435;&#x00441;&#x00441;, &#x00435;&#x00441;&#x0043b;&#x00438; &#x0043d;&#x00435; &#x00443;&#x00434;&#x00435;&#x0043b;&#x0044f;&#x00442;&#x0044c; &#x00438;&#x0043c; &#x00434;&#x0043e;&#x0043b;&#x00436;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00432;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x0043d;&#x00438;&#x0044f;. &#x00412; &#x00441;&#x00442;&#x00430;&#x00442;&#x0044c;&#x00435; &#x00440;&#x00430;&#x00441;&#x00441;&#x0043c;&#x00430;&#x00442;&#x00440;&#x00438;&#x00432;&#x00430;&#x0044e;&#x00442;&#x00441;&#x0044f; &#x0043d;&#x00435;&#x00434;&#x00430;&#x00432;&#x0043d;&#x00438;&#x00435; &#x00440;&#x00430;&#x00437;&#x00440;&#x00430;&#x00431;&#x0043e;&#x00442;&#x0043a;&#x00438; &#x00432; &#x0043e;&#x00431;&#x0043b;&#x00430;&#x00441;&#x00442;&#x00438; &#x00434;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x0044d;&#x0043a;&#x00441;&#x0043f;&#x00440;&#x00435;&#x00441;&#x00441;-&#x00442;&#x00435;&#x00441;&#x00442;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043d;&#x00430; &#x0043c;&#x00430;&#x0043b;&#x0044f;&#x00440;&#x00438;&#x0044e;, &#x0043e;&#x00441;&#x00432;&#x00435;&#x00449;&#x00430;&#x0044e;&#x00442;&#x00441;&#x0044f; &#x0043d;&#x00435;&#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00435; &#x00438;&#x00437; &#x0043f;&#x00440;&#x0043e;&#x00431;&#x0043b;&#x00435;&#x0043c;, &#x00430; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043b;&#x00430;&#x00433;&#x00430;&#x0044e;&#x00442;&#x00441;&#x0044f; &#x00441;&#x0043f;&#x0043e;&#x00441;&#x0043e;&#x00431;&#x0044b; &#x00440;&#x00435;&#x00430;&#x00433;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043d;&#x00430; &#x0044d;&#x00442;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00431;&#x0043b;&#x00435;&#x0043c;&#x0044b;.</p></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>In the 1950s, the World Health Organization (WHO) launched a global malaria eradication programme based primarily on a strategy of vector control with insecticides supplemented with mass drug administration to people living in malaria-endemic countries outside sub-Saharan Africa.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> While nearly 40 countries succeeded in eliminating malaria in the 1950s and 1960s, many did not, and the programme eventually collapsed.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="R3" ref-type="bibr"><sup>3</sup></xref> In recent years, a renewed interest in, and commitment to, malaria elimination has emerged.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> WHO developed the global technical strategy that aims to eliminate malaria in at least 35 countries by 2030 in close coordination with the Roll Back Malaria Partnership.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p>In the absence of accurate diagnostic tests, presumptive treatment or clinical diagnosis of malaria can result in the treatment of patients who do not actually have malaria,<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="R7" ref-type="bibr"><sup>7</sup></xref> contributing to overtreatment, wasted resources<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> and antimalarial medicine resistance.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> Since the early 1900s, microscopy has been the primary method used to diagnose malaria.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> In this paper, we examine the introduction of a new method to diagnose malaria &#x02013; a rapid diagnostic test that uses monoclonal antibodies to detect malaria antigens in a drop of the patient&#x02019;s blood. We describe recent developments that have spurred the growth in demand for rapid diagnostic tests for malaria, identify challenges that could limit further progress and make recommendations that could help mitigate these challenges.</p></sec><sec><title>Rapid diagnostic tests</title><p>Quality assured microscopic examination of Giemsa-stained blood smears detecting malaria parasites is the gold standard in malaria diagnosis.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> However, microscopy requires trained technicians, a basic laboratory infrastructure and quality equipment and reagents. Because of these requirements, field microscopy is often performed inaccurately, especially in rural settings or in places where little malaria is found.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="R10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="R11" ref-type="bibr"><sup>11</sup></xref></p><p>In the 1990s, new methods to detect malaria were introduced, including molecular methods that can detect infections at very low parasite levels and antigen detection that can be used by remote health workers in areas where microscopy is impractical.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> Unlike microscopy or molecular methods, rapid diagnostic tests require little training and the result is available after 15 to 30 minutes. Furthermore, rapid diagnostic tests require no laboratory infrastructure, allowing them to be deployed to the most remote settings. <xref ref-type="table" rid="T1">Table&#x000a0;1</xref> provides an overview of the available diagnostic methods for malaria.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Malaria diagnostic technologies</title></caption><table frame="hsides" rules="groups"><col width="99" span="1"/><col width="123" span="1"/><col width="95" span="1"/><col width="182" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Method</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Description</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Use</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Characteristics</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Antigen detection (rapid diagnostic test)</td><td valign="top" align="left" rowspan="1" colspan="1">Disposable tests that detect antigens produced by malaria parasite; requires minimal training</td><td valign="top" align="left" rowspan="1" colspan="1">319 million rapid diagnostic tests in 2013<sup>a</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Rapidly growing market; size and growth attractive to suppliers; relatively low unit cost; research and development incremental, e.g. improving existing products to meet minimum standards</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Microscopy</td><td valign="top" align="left" rowspan="1" colspan="1">Direct visualization of parasite using microscope and stained slides; requires trained technicians</td><td valign="top" align="left" rowspan="1" colspan="1">Approximately 197 million slides read and reported in 2013<sup>a</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Mature, stable market; multiple suppliers of equipment, regents and consumables; low unit cost (especially at high volumes); research and development largely focused on developing automated systems</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Nucleic acid testing</td><td valign="top" align="left" rowspan="1" colspan="1">Detection of parasite ribonucleic or deoxyribonucleic acid; requires sophisticated laboratory, instruments and trained technicians</td><td valign="top" align="left" rowspan="1" colspan="1">Small niche market; used for research, surveillance and as reference standard</td><td valign="top" align="left" rowspan="1" colspan="1">Little standardization of methods, limited availability of commercial test kits; relatively high unit cost per test; research and development focuses on development of point-of-care devices and test kits, rather than low cost</td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>World Malaria Report 2014. Geneva: World Health Organization; 2014.</p></table-wrap-foot></table-wrap><p>In subsequent years, the large potential market for malaria diagnostics attracted many suppliers: by 2005 about 60 manufacturers were supplying rapid diagnostic tests.<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> Results from field trials suggested highly variable performance but there was no system in place at a global level to independently assess and compare the performance of the tests.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref></p><p>In 2008, WHO, the US Centers for Disease Control and Prevention and the Foundation for Innovative Diagnostics jointly implemented an evaluation programme, which coupled pre-purchase product evaluation (product testing) with a post-purchase lot verification service, to assess, review and compare the performance of malaria rapid diagnostic tests in a standardized manner. In this product testing scheme, tests provided by ISO13485-certified manufacturers are rigorously evaluated against blood samples containing <italic>Plasmodium falciparum</italic> or <italic>Plasmodium vivax</italic> and malaria-negative samples. The rapid diagnostic tests also undergo limited heat stability testing (incubated for 60 days at 35&#x000a0;&#x000b0;C and 45&#x000a0;&#x000b0;C). This challenge covers the upper limit of storage conditions recommended by rapid diagnostic test manufacturers (i.e. 35&#x02013;40&#x000a0;&#x000b0;C); but is shorter than the typical product shelf-life of 18&#x02013;24&#x000a0;months.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></p><p>The product evaluation programme demonstrated convincingly that some rapid diagnostic tests can consistently detect malaria at the lower limits of clinically significant disease and with very low false-positive rates.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> These findings were confirmed in future rounds of testing and have contributed to the broader acceptance of rapid diagnostic tests as a reliable diagnostic tool. WHO has established recommended minimum rapid diagnostic test performance criteria to inform procurement (<xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>). Major procurers &#x02013; including other United Nations agencies, the Global Fund to fight AIDS, Tuberculosis and Malaria and the President&#x02019;s Malaria Initiative &#x02013; have adopted these criteria. The use of rapid diagnostic tests shifted to products that scored highly in the evaluation programme, a trend that continues in the public sector today.</p><boxed-text id="B1" position="float" orientation="portrait"><label>Box&#x000a0;1</label><caption><title>World Health Organization procurement criteria for malaria rapid diagnostic tests</title></caption><p>Products should be selected in line with the following set of criteria, based on the results of the assessment of the World Health Organization malaria product testing programme:</p><list list-type="order" id="L1"><list-item><p>For the detection of <italic>Plasmodium falciparum</italic> in all transmission settings the panel detection score against <italic>P. falciparum</italic> samples should be at least 75% at 200 parasites/&#x003bc;L.</p></list-item><list-item><p>For the detection of <italic>Plasmodium vivax</italic> in all transmission settings the panel detection score against <italic>P. vivax</italic> samples should be at least 75% at 200 parasites/&#x003bc;L.</p></list-item><list-item><p>There should be less than 10% false-positive test results and less than 5% invalid results.</p></list-item></list><p>Only products meeting performance criteria outlined above are recommended for procurement.</p></boxed-text><p>The results of the five evaluation rounds published so far, including 147 unique products, show that tests for <italic>P. falciparum</italic> that target the histidine rich protein II antigen have the highest detection scores at low parasite density. A smaller number of tests detecting <italic>P. vivax</italic>, targeting plasmodium lactate dehydrogenase or aldolase antigens also perform well.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> Most high-performing rapid diagnostic tests are also heat stable.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> These results are generally consistent with recent studies evaluating the performance of rapid diagnostic tests in the field.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="R17" ref-type="bibr"><sup>17</sup></xref></p><sec><title>Demand for rapid tests</title><p>In 2010, WHO began to recommend confirmation of all suspected malaria cases by microscopy or rapid diagnostic test before treatment<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> and subsequently WHO and the Roll Back Malaria Partnership set ambitious targets to achieve universal access to testing for all patients suspected of having malaria.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> As a result, there has been a rapid increase in diagnostic testing for malaria in recent years, primarily driven by the uptake of rapid diagnostic tests in the public sector. Global sales volumes for rapid diagnostic tests rose from 48 million in 2008, to 319 million in 2013 and in many settings rapid diagnostic test use surpassed microscopy for malaria diagnosis.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="R21" ref-type="bibr"><sup>21</sup></xref> Rapid diagnostic tests are also used in private retail settings in countries where this sector plays a significant role in malaria case management.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>&#x02013;</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref></p><p>Rapid diagnostic tests also play an important role in detecting clinically significant malaria in settings that have reduced their malaria transmission to very low levels.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref> There is an emerging need for tests that can detect malaria in the asymptomatic population with even lower levels of infection.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref> There are uncertainties about the optimal limit of detection and trade-offs between performance, ease of use and the time taken to obtain test results.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> The use of rapid tests will depend on the malaria elimination strategies that countries chose to adopt, including whether and to what effect mass screening and treatment strategies are deployed.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref> Finally, given the decline in malaria burden, most malaria tests will be negative and the current generation of rapid diagnostic tests presents health workers with the challenge of diagnosing and managing fevers that are not caused by malaria. Experience is growing with algorithmic approaches to managing these cases.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref> New diagnostic tools for other febrile illnesses and for biomarkers that can help identify severe disease may be available in the future.<xref rid="R31" ref-type="bibr"><sup>31</sup></xref> In summary, we expect that demand for rapid diagnostic tests will continue to expand. Despite these gains, UNITAID&#x02019;s market landscape reports<xref rid="R32" ref-type="bibr"><sup>32</sup></xref> as well as recent procurement and costing data analyses highlight potential challenges that, if unaddressed, jeopardize the progress made to date.</p></sec><sec><title>Future challenges</title><p>A limited number of manufacturers supply the global public health market, despite a large number of eligible manufacturers. Because the process for achieving WHO prequalification status has been slow in recent years, most countries and international funders continue to use procurement criteria based on results from the WHO testing programme. While 29 manufacturers meet WHO&#x02019;s recommended procurement criteria, data from the Global Fund and the President&#x02019;s Malaria Initiative indicate that three manufacturers won 92% of tenders in 2013. Furthermore, since one of the three highest-volume manufacturers procures major components from one of the other two manufacturers, 92% of the public sector supply is essentially dependent on only two manufacturers.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref> Although the two manufacturers have sufficient annual production capacity to meet current global demand, quality or capacity issues at one manufacturer could cause global supply shortages.</p><p>From 2010 to 2014, ex-factory prices for rapid malaria tests decreased by nearly 50%. Recent procurement data show that prices in some tenders are as low as 0.18 United States dollars (US$) per test.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> While price reductions were expected due to competition and economies of scale, the recent prices may be too low. The cost of production is estimated to be US$&#x000a0;0.16 to US$&#x000a0;0.23, depending on the level of automation, production volumes and allocation of indirect costs. Low prices for the public sector have caused some manufacturers to exit the market; for those that remain, the low margins may discourage research and development. Low prices could compromise quality and ultimately performance, by leading manufacturers to cut corners in their production.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="R35" ref-type="bibr"><sup>35</sup></xref></p><p>Most procurers award annual tenders to a single manufacturer. This results in shorter lead times and higher production and transport costs for manufacturers. Because manufacturers do not know if they will win or lose a tender, they are unable to accurately plan production. Given uncertain demand and low margins, most manufacturers carry little stock of raw materials and finished products. Once a tender is won, manufacturers have to rapidly procure materials at higher prices due to spot contracts and higher transport costs to ship the materials immediately. Furthermore, manufacturers experience busy months producing at capacity using multiple shifts a day to fill a tender, which in turn results in increased labour costs.</p><p>Despite WHO&#x02019;s product testing programme, gaps still exist in quality control and quality assurance. With respect to product testing, manufacturers can produce (or procure) rapid diagnostic test batches exclusively for submission to the product testing programme. In addition, although nearly all lots tested pass the minimum performance thresholds in lot testing, many of the rapid diagnostic tests are not randomly sampled, since they are often sent directly by the manufacturer to the testing laboratory. In malaria endemic countries, post marketing surveillance is nearly non-existent; there are no practical tools that can be used by central reference laboratories or at point-of-care to check that rapid diagnostic tests are still performing acceptably after they are delivered. Few countries have a robust surveillance system to monitor rapid diagnostic test use in facilities and to document abnormalities and failures.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref></p><p>A weak regulatory environment at the country level may lead to substandard rapid diagnostic tests being imported and deter manufacturers from entering the market.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref> Lengthy registration processes, which have to be completed separately in each country, also act as barriers to market entry. In some countries, different authorities or professional associations regulate the sale and use of in vitro diagnostics, but roles may overlap and resources may be insufficient to implement the regulatory controls. If substandard rapid diagnostic tests enter the market without regulatory controls being enforced, manufacturers will need to compete against these products. In Uganda, for example, almost 20% of private pharmacies carried rapid diagnostic tests that had not been evaluated by WHO&#x02019;s testing programme.<xref rid="R37" ref-type="bibr"><sup>37</sup></xref> Many countries have yet to determine which outlet types or providers can administer or sell rapid diagnostic tests. These decisions will affect access, especially to diagnosis by the private sector, which treats an estimated 30&#x02013;50% of people with fever in countries where malaria is common.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref></p></sec></sec><sec><title>Recommendations</title><p>To address some of the challenges described above, we propose the following recommendations. First, donors, procurement bodies and countries should increase their focus on quality. Although price will continue to be a driving force, it should not be the key factor that determines public tender selection. Since 2009, donors and major procurers have aligned rapid diagnostic test selection criteria that emphasize minimum performance requirements and lot testing. Eventually, they could also publicly agree to buy only WHO prequalified rapid diagnostic tests so as to encourage manufacturers to achieve this high standard. Recently, the major manufacturers have prequalified five rapid diagnostic tests for malaria.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref> Procurers could hire sampling agents to randomly select rapid test products. Donors and procurers could also prioritize the adoption and roll out of quality control tools (e.g. positive controls or recombinant antigen reference panels) to support post market surveillance.</p><p>Second, the global malaria community should work together to harmonize rapid diagnostic tests with international standards and evidence to promote best practices in production, packaging and test procedures. In 2013, the Roll Back Malaria Partnership studied how rapid diagnostic tests could be harmonized to promote appropriate use and reduce operator errors. Best practices for device labelling, packaging, accessories and instructions for use were developed. Future efforts could include harmonization of test procedures, reducing the need for re-training following the introduction of new tests, but the technical and regulatory implications of such changes require careful consideration.</p><p>Third, long-term agreements with several manufacturers could contribute to low prices without putting manufacturers out of business. If manufacturers obtain volume commitments for at least one or two years, cost efficiencies can be achieved through reduced prices of materials, lower labour costs, improved production schedules and better inventory management. In pursuing these longer-term agreements, volumes should be split appropriately between eligible manufacturers.</p><p>Fourth, donors, countries and the global malaria community could work to strengthen national legal frameworks for regulation of in vitro diagnostic tests.<xref rid="R39" ref-type="bibr"><sup>39</sup></xref> Wherever possible, adoption of harmonized registration requirements, quality standards and regional mechanisms (e.g. regional networks of accredited laboratories to facilitate batch testing or other quality control activities) could promote best practices, avoid duplication of efforts and minimize the burden on regulators and manufacturers alike.<xref rid="R40" ref-type="bibr"><sup>40</sup></xref> In the short term, there is a need to provide manufacturers and importers with information on how to register rapid diagnostic tests and stipulate who may perform the test under what conditions. Given the scale up of rapid diagnostic tests for malaria and the continuing need for innovation, the stakes are particularly high. Our recommendations can help enhance quality, reduce costs, encourage innovation and increase the availability of rapid diagnostic tests.</p></sec></body><back><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Russell</surname>
<given-names>TL</given-names></string-name>, <string-name><surname>Beebe</surname>
<given-names>NW</given-names></string-name>, <string-name><surname>Cooper</surname>
<given-names>RD</given-names></string-name>, <string-name><surname>Lobo</surname>
<given-names>NF</given-names></string-name>, <string-name><surname>Burkot</surname>
<given-names>TR</given-names></string-name>. <article-title>Successful malaria elimination strategies require interventions that target changing vector behaviours.</article-title>
<source>Malar J</source>. <year>2013</year>;<volume>12</volume>(<issue>1</issue>):<fpage>56</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2875-12-56</pub-id><pub-id pub-id-type="pmid">23388506</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Wongsrichanalai</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Barcus</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Muth</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sutamihardja</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wernsdorfer</surname>
<given-names>WH</given-names></string-name>. <article-title>A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT).</article-title>
<source>Am J Trop Med Hyg</source>. <year>2007</year>
<month>12</month>;<volume>77</volume>(<issue>6</issue>) <supplement>Suppl</supplement>:<fpage>119</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">18165483</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>N&#x000e1;jera</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Gonz&#x000e1;lez-Silva</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Alonso</surname>
<given-names>PL</given-names></string-name>. <article-title>Some lessons for the future from the Global Malaria Eradication Programme (1955&#x02013;1969).</article-title>
<source>PLoS Med</source>. <year>2011</year>;<volume>8</volume>(<issue>1</issue>):<fpage>e1000412</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1000412</pub-id><pub-id pub-id-type="pmid">21311585</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>White</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Pukrittayakamee</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Hien</surname>
<given-names>TT</given-names></string-name>, <string-name><surname>Faiz</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Mokuolu</surname>
<given-names>OA</given-names></string-name>, <string-name><surname>Dondorp</surname>
<given-names>AM</given-names></string-name>. <article-title>Malaria.</article-title>
<source>Lancet</source>. <year>2014</year>
<month>2</month>
<day>22</day>;<volume>383</volume>(<issue>9918</issue>):<fpage>723</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)60024-0</pub-id><pub-id pub-id-type="pmid">23953767</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="web">Global technical strategy for malaria 2016&#x02013;2030. Geneva: World Health Organization; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/publications/atoz/9789241564991/en/">http://www.who.int/malaria/publications/atoz/9789241564991/en/</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 Aug 5].</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Perkins</surname>
<given-names>MD</given-names></string-name>, <string-name><surname>Bell</surname>
<given-names>DR</given-names></string-name>. <article-title>Working without a blindfold: the critical role of diagnostics in malaria control.</article-title>
<source>Malar J</source>. <year>2008</year>;<volume>7</volume>
<issue>Suppl 1</issue>:<fpage>S5</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2875-7-S1-S5</pub-id><pub-id pub-id-type="pmid">19091039</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Chandramohan</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Jaffar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Greenwood</surname>
<given-names>B</given-names></string-name>. <article-title>Use of clinical algorithms for diagnosing malaria.</article-title>
<source>Trop Med Int Health</source>. <year>2002</year>
<month>1</month>;<volume>7</volume>(<issue>1</issue>):<fpage>45</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-3156.2002.00827.x</pub-id><pub-id pub-id-type="pmid">11851954</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Cohen</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Woolsey</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Sabot</surname>
<given-names>OJ</given-names></string-name>, <string-name><surname>Gething</surname>
<given-names>PW</given-names></string-name>, <string-name><surname>Tatem</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Moonen</surname>
<given-names>B</given-names></string-name>. <article-title>Public health. Optimizing investments in malaria treatment and diagnosis.</article-title>
<source>Science</source>. <year>2012</year>
<month>11</month>
<day>2</day>;<volume>338</volume>(<issue>6107</issue>):<fpage>612</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1126/science.1229045</pub-id><pub-id pub-id-type="pmid">23118172</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>White</surname>
<given-names>NJ</given-names></string-name>. <article-title>Antimalarial drug resistance.</article-title>
<source>J Clin Invest</source>. <year>2004</year>
<month>4</month>;<volume>113</volume>(<issue>8</issue>):<fpage>1084</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1172/JCI21682</pub-id><pub-id pub-id-type="pmid">15085184</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Bell</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wongsrichanalai</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Barnwell</surname>
<given-names>JW</given-names></string-name>. <article-title>Ensuring quality and access for malaria diagnosis: how can it be achieved?</article-title>
<source>Nat Rev Microbiol</source>. <year>2006</year>
<month>9</month>;<volume>4</volume>(<issue>9</issue>):<fpage>682</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro1474</pub-id><pub-id pub-id-type="pmid">16912713</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="book"><source>Malaria light microscopy: creating a culture of quality.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2008</year>.</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="web">WHO-FIND malaria RDT evaluation programme: an international collaboration for quality control of malaria rapid diagnostic tests. Geneva: World Health Organization; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/mpac/mpac-sept2014-round5-product-testing-presentation.pdf">http://www.who.int/malaria/mpac/mpac-sept2014-round5-product-testing-presentation.pdf</ext-link> [cited 2015 Aug 5].</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Murray</surname>
<given-names>CK</given-names></string-name>, <string-name><surname>Gasser</surname>
<given-names>RA</given-names>
<suffix>Jr</suffix></string-name>, <string-name><surname>Magill</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Miller</surname>
<given-names>RS</given-names></string-name>. <article-title>Update on rapid diagnostic testing for malaria.</article-title>
<source>Clin Microbiol Rev</source>. <year>2008</year>
<month>1</month>;<volume>21</volume>(<issue>1</issue>):<fpage>97</fpage>&#x02013;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00035-07</pub-id><pub-id pub-id-type="pmid">18202438</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="web">Methods manual for laboratory quality control testing of malaria rapid diagnostic tests. Geneva: Foundation for Innovative Diagnostics; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.finddiagnostics.org/export/sites/default/programs/malaria-afs/docs/Methods_manual_for_laboratory_qc_testing_malaria_RDTs_vers7.pdf">http://www.finddiagnostics.org/export/sites/default/programs/malaria-afs/docs/Methods_manual_for_laboratory_qc_testing_malaria_RDTs_vers7.pdf</ext-link> [cited 2015 Aug 5].</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="web">Malaria rapid diagnostic test performance: Summary results of WHO product testing of malaria rapid diagnostic tests: Round 1&#x02013;5. Geneva: World Health Organization; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/publications/atoz/9789241507554/en/">http://www.who.int/malaria/publications/atoz/9789241507554/en/</ext-link> [cited 2015 Sep 1].</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Abba</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Deeks</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Olliaro</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Naing</surname>
<given-names>C-M</given-names></string-name>, <string-name><surname>Jackson</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Takwoingi</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal>
<article-title>Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries.</article-title>
<source>Cochrane Database Syst Rev</source>. <year>2011</year>; (<issue>7</issue>):<fpage>CD008122</fpage>.<pub-id pub-id-type="pmid">21735422</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Abba</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kirkham</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Olliaro</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Deeks</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Donegan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Garner</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or Plasmodium vivax malaria in endemic countries.</article-title>
<source>Cochrane Database Syst Rev</source>. <year>2014</year>;<volume>12</volume>:<fpage>CD011431</fpage>.<pub-id pub-id-type="pmid">25519857</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="book"><source>Guidelines for the treatment of malaria.</source>
<edition>2nd ed.</edition>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="book"><source>Refined/updated GMAP objectives: Targets, milestones and priorities beyond 2011.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>Roll Back Malaria</publisher-name>; <year>2011</year>.</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="web">Malaria diagnostics technology and market landscape. Geneva: UNITAID; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.unitaid.eu/images/projects/malaria/2014_Malaria_Diagnostics_Landscape_2nd_edition.pdf">http://www.unitaid.eu/images/projects/malaria/2014_Malaria_Diagnostics_Landscape_2nd_edition.pdf</ext-link> [cited 2015 Sep 1].</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="book"><source>World malaria report 2013.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Mbonye</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Magnussen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lal</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Hansen</surname>
<given-names>KS</given-names></string-name>, <string-name><surname>Cundill</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Chandler</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal>
<article-title>A cluster randomised trial introducing rapid diagnostic tests into registered drug shops in Uganda: Impact on appropriate treatment of malaria.</article-title>
<source>PLoS ONE</source>. <year>2015</year>;<volume>10</volume>(<issue>7</issue>):<fpage>e0129545</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0129545</pub-id><pub-id pub-id-type="pmid">26200467</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Cohen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Fink</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Maloney</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Berg</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Jordan</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Svoronos</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>Introducing rapid diagnostic tests for malaria to drug shops in Uganda: a cluster-randomized controlled trial.</article-title>
<source>Bull World Health Organ</source>. <year>2015</year>;<volume>93</volume>(<issue>3</issue>):<fpage>142</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.14.142489</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Ansah</surname>
<given-names>EK</given-names></string-name>, <string-name><surname>Narh-Bana</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Affran-Bonful</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Bart-Plange</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Cundill</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Gyapong</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>The impact of providing rapid diagnostic malaria tests on fever management in the private retail sector in Ghana: a cluster randomized trial.</article-title>
<source>BMJ</source>. <year>2015</year>;<volume>350</volume>
<issue>mar04 8</issue>:<fpage>h1019</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.h1019</pub-id><pub-id pub-id-type="pmid">25739769</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="book"><source>WHO policy brief on malaria diagnostics in elimination settings.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>McMorrow</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Aidoo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kachur</surname>
<given-names>SP</given-names></string-name>. <article-title>Malaria rapid diagnostic tests in elimination settings&#x02013;can they find the last parasite?</article-title>
<source>Clin Microbiol Infect</source>. <year>2011</year>
<month>11</month>;<volume>17</volume>(<issue>11</issue>):<fpage>1624</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03639.x</pub-id><pub-id pub-id-type="pmid">21910780</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Sturrock</surname>
<given-names>HJW</given-names></string-name>, <string-name><surname>Hsiang</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Cohen</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Greenhouse</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Bousema</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>Targeting asymptomatic malaria infections: active surveillance in control and elimination.</article-title>
<source>PLoS Med</source>. <year>2013</year>;<volume>10</volume>(<issue>6</issue>):<fpage>e1001467</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001467</pub-id><pub-id pub-id-type="pmid">23853551</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Tanner</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Greenwood</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Whitty</surname>
<given-names>CJM</given-names></string-name>, <string-name><surname>Ansah</surname>
<given-names>EK</given-names></string-name>, <string-name><surname>Price</surname>
<given-names>RN</given-names></string-name>, <string-name><surname>Dondorp</surname>
<given-names>AM</given-names></string-name>, <etal>et al.</etal>
<article-title>Malaria eradication and elimination: views on how to translate a vision into reality.</article-title>
<source>BMC Med</source>. <year>2015</year>;<volume>13</volume>(<issue>1</issue>):<fpage>167</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-015-0384-6</pub-id><pub-id pub-id-type="pmid">26208740</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Stresman</surname>
<given-names>GH</given-names></string-name>, <string-name><surname>Baidjoe</surname>
<given-names>AY</given-names></string-name>, <string-name><surname>Stevenson</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Grignard</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Odongo</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Owaga</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal>
<article-title>Focal screening to identify the subpatent parasite reservoir in an area of low and heterogeneous transmission in the Kenya highlands.</article-title>
<source>J Infect Dis</source>. <year>2015</year>
<month>5</month>
<day>27</day>; <pub-id pub-id-type="doi">10.1093/infdis/jiv302</pub-id><pub-id pub-id-type="pmid">26019285</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="book"><string-name><surname>D&#x02019;Acremont</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Bosman</surname>
<given-names>A</given-names></string-name>. <source>WHO informal consultation on fever management in peripheral health care settings: a global review of evidence and practice.</source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Chappuis</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Alirol</surname>
<given-names>E</given-names></string-name>, <string-name><surname>d&#x02019;Acremont</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Bottieau</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Yansouni</surname>
<given-names>CP</given-names></string-name>. <article-title>Rapid diagnostic tests for non-malarial febrile illness in the tropics.</article-title>
<source>Clin Microbiol Infect</source>. <year>2013</year>
<month>5</month>;<volume>19</volume>(<issue>5</issue>):<fpage>422</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/1469-0691.12154</pub-id><pub-id pub-id-type="pmid">23413992</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="web">Daily J. Malaria diagnostics technology and market landscape. UNITAID 2014 Available from: <ext-link ext-link-type="uri" xlink:href="http://www.unitaid.eu/images/projects/malaria/2014_Malaria_Diagnostics_Landscape_2nd_edition.pdf">http://www.unitaid.eu/images/projects/malaria/2014_Malaria_Diagnostics_Landscape_2nd_edition.pdf</ext-link> [cited 2015 Sep 23].</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="web">Price and quality reporting [Internet]. Geneva: The Global Fund to Fight AIDS, Tuberculosis and Malaria: 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://pqr.theglobalfund.org/Screens/PQRLogin.aspx?Lang=en-GB">http://pqr.theglobalfund.org/Screens/PQRLogin.aspx?Lang=en-GB</ext-link> [cited 2015 Sep 23].</mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Gillet</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Maltha</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hermans</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Ravinetto</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bruggeman</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Jacobs</surname>
<given-names>J</given-names></string-name>. <article-title>Malaria rapid diagnostic kits: quality of packaging, design and labelling of boxes and components and readability and accuracy of information inserts.</article-title>
<source>Malar J</source>. <year>2011</year>;<volume>10</volume>(<issue>1</issue>):<fpage>39</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2875-10-39</pub-id><pub-id pub-id-type="pmid">21314992</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Barb&#x000e9;</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Gillet</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Beelaert</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Fransen</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Jacobs</surname>
<given-names>J</given-names></string-name>. <article-title>Assessment of desiccants and their instructions for use in rapid diagnostic tests.</article-title>
<source>Malar J</source>. <year>2012</year>;<volume>11</volume>(<issue>1</issue>):<fpage>326</fpage>. <pub-id pub-id-type="doi">10.1186/1475-2875-11-326</pub-id><pub-id pub-id-type="pmid">22974115</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><string-name><surname>Rugera</surname>
<given-names>SP</given-names></string-name>, <string-name><surname>McNerney</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Poon</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Akimana</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Mariki</surname>
<given-names>RF</given-names></string-name>, <string-name><surname>Kajumbula</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal>
<article-title>Regulation of medical diagnostics and medical devices in the East African community partner states.</article-title>
<source>BMC Health Serv Res</source>. <year>2014</year>;<volume>14</volume>(<issue>1</issue>):<fpage>524</fpage>. <pub-id pub-id-type="doi">10.1186/s12913-014-0524-2</pub-id><pub-id pub-id-type="pmid">25366990</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><string-name><surname>Poyer</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Shewchuk</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Tougher</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ye</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Mann</surname>
<given-names>AG</given-names></string-name>, <string-name><surname>Willey</surname>
<given-names>BA</given-names></string-name>, <etal>et al.</etal>; <collab>ACTwatch Group</collab>. <article-title>Availability and price of malaria rapid diagnostic tests in the public and private health sectors in 2011: results from 10 nationally representative cross-sectional retail surveys.</article-title>
<source>Trop Med Int Health</source>. <year>2015</year>
<month>6</month>;<volume>20</volume>(<issue>6</issue>):<fpage>744</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1111/tmi.12491</pub-id><pub-id pub-id-type="pmid">25728761</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="web">WHO list of prequalified in vitro diagnostic products [Internet]. Geneva: World Health Organization; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/diagnostics_laboratory/evaluations/PQ_list/">http://www.who.int/diagnostics_laboratory/evaluations/PQ_list/</ext-link> [cited 2015 Sep 23].</mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="book"><source>Resolution WHA67.20. Regulatory system strengthening for medical products. In: Sixty-seventh World Health Assembly, Geneva, 19&#x02013;24 May 2014. </source><publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><string-name><surname>McNerney</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Sollis</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Peeling</surname>
<given-names>RW</given-names></string-name>. <article-title>Improving access to new diagnostics through harmonised regulation: priorities for action.</article-title>
<source>Afr J Lab Med</source>. <year>2014</year>
<month>4</month>;<volume>3</volume>(<issue>1</issue>): <pub-id pub-id-type="doi">10.4102/ajlm.v3i1.123</pub-id></mixed-citation></ref></ref-list></back></article>